Data Insights

Poseltinib by Hanmi Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval

Poseltinib is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Poseltinib in Follicular Lymphoma

Data Insights

Poseltinib by Hanmi Pharmaceuticals for Autoimmune Disorders: Likelihood of Approval

Poseltinib is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Autoimmune Disorders. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Poseltinib in Autoimmune Disorders

Data Insights

HCP-1803 by Hanmi Pharmaceuticals for Idiopathic (Essential) Hypertension: Likelihood of Approval

HCP-1803 is under clinical development by Hanmi Pharmaceuticals and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - HCP-1803 in Idiopathic (Essential) Hypertension

Data Insights

Poseltinib by Hanmi Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Poseltinib is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Poseltinib in Diffuse Large B-Cell Lymphoma

Data Insights

Encequidar mesylate + paclitaxel by Hanmi Pharmaceuticals for Breast Cancer: Likelihood of Approval

Encequidar mesylate + paclitaxel is under clinical development by Hanmi Pharmaceuticals and currently in Phase II for Breast Cancer. According...

Data Insights

BH-3120 by Hanmi Pharmaceuticals for Solid Tumor: Likelihood of Approval

BH-3120 is under clinical development by Hanmi Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BH-3120 in Solid Tumor

Data Insights

HCP-1803 by Hanmi Pharmaceuticals for Idiopathic (Essential) Hypertension: Likelihood of Approval

HCP-1803 is under clinical development by Hanmi Pharmaceuticals and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - HCP-1803 in Idiopathic (Essential) Hypertension